[1] Yu W, Clyne M, Khoury MJ, Gwinn M. Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics, 2010, 26(1): 145-146.[2] Stearns FW. One hundred years of pleiotropy: a retrospective. Genetics, 2010, 186(3): 767-773.[3] Becker KG. The common variants/multiple disease hypothesis of common complex genetic disorders. Med Hypotheses, 2004, 62(2): 309-317.[4] Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P. Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis, 2012, 27(2): 211-218.[5] Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci USA, 2007, 104(21): 8685-8690.[6] Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T, Rudan I, McKeigue P, Wilson JF, Campbell H. Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet, 2011, 89(5): 607-618.[7] 姚晨, 张敏, 邹金凤, 李红东, 王栋, 朱晶, 郭政. 可识别多种癌症的基因功能模块. 中国科学 C辑: 生命科学, 2009, 39(11): 1092-1096.[8] Gu X. Evolutionary framework for protein sequence evolution and gene pleiotropy. Genetics, 2007, 175(4): 1813-1822.[9] 朱晶, 沈晓沛, 肖会, 张杨, 王靖, 郭政. 基于共进化基因功能模块发现候选癌基因. 遗传, 2010, 32(7): 694-700.[10] Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucl Acids Res, 2003, 31(4): e15.[11] Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 2004, 20(3): 307-315.[12] Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 2004, 3(1): Article3.[13] Tanay A, Sharan R, Kupiec M, Shamir R. Revealing modularity and organization in the yeast molecular network by integrated analysis of highly heterogeneous genomewide data. Proc Natl Acad Sci USA, 2004, 101(9): 2981-2986.[14] Tanay A, Sharan R, Shamir R. Discovering statistically significant biclusters in gene expression data. Bioinformatics, 2002, 18(Suppl. 1): S136-S144.[15] Shamir R, Maron-Katz A, Tanay A, Linhart C, Steinfeld I, Sharan R, Shiloh Y, Elkon R. EXPANDER-an integrative program suite for microarray data analysis. BMC Bioinformatics, 2005, 6: 232, doi: 10.1186/1471-2105-6-232.[16] Li WT, Wang R, Bai LF, Yan ZM, Sun ZR. Cancer core modules identification through genomic and transcriptomic changes correlation detection at network level. BMC Syst Biol, 2012, 6: 64, doi: 10.1186/1752-0509-6-64.[17] Yu Y, Feng YM. The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer, 2010, 116(22): 5150-5160.[18] Liu ZJ, Ling K, Wu X, Cao J, Liu B, Li SY, Si Q, Cai Y, Yan C, Zhang Y, Weng YG. Reduced expression of cenp-e in human hepatocellular carcinoma. J Exp Clin Cancer Res, 2009, 28: 156, doi:10.1186/1756-9966-28-156.[19] Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med, 2011, 15(3): 501-513.[20] Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer, 2012, 131(4): 911-923.[21] Wolkersdorfer T, Füssel M, Kiesslich T, Neureiter D, Berr F, Aust D, Wolkersdorfer GW. MHC class II genotype- and MHC class I and II phenotype-related parameters in sporadic colorectal cancer. Oncol Rep, 2011, 26(5): 1165-1171.[22] Kouno M, Kondoh G, Horie K, Komazawa N, Ishii N, Takahashi Y, Takeda J, Hashimoto T. Ahnak/Desmoyokin is dispensable for proliferation, differentiation, and maintenance of integrity in mouse epidermis. J Invest Dermatol, 2004, 123(4): 700-707.[23] Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, Leone G, Wolf R, Yuspa SH, Ganju RK. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res, 2012, 72(3): 604-615.[24] Pasini FS, Maistro S, Snitcovsky I, Barbeta LP, Rotea Mangone FR, Lehn CN, Walder F, Carvalho MB, Brentani MM, Federico MH. Four-gene expression model predictive of lymph node metastases in oral squamous cell carcinoma. Acta Oncol, 2012, 51(1): 77-85.[25] Tesfaigzi Y, Wright PS, Belinsky SA. SPRR1B overexpression enhances entry of cells into the G0 phase of the cell cycle. Am J Physiol Lung Cell Mol Physiol, 2003, 285(4): L889-L898.[26] Ruangpanit N, Chan D, Holmbeck K, Birkedal-Hansen H, Polarek J, Yang CL, Bateman JF, Thompson E W. Gelatinase A (MMP-2) activation by skin fibroblasts: dependence on MT1-MMP expression and fibrillar collagen form. Matrix Biol, 2001, 20(3): 193-203.[27] Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer, 2004, 4(11): 891-899.[28] Lin X, Chen YG, Meng AM, Feng XH. Termination of TGF-β superfamily signaling through SMAD dephosphorylation-a functional genomic view. J Genet Genomics, 2007, 34(1): 1-9.[29] Du Y, Liu YW, Wang YZ, He YQ, Yang CX, Gao F. LYVE-1 enhances the adhesion of HS-578T cells to COS- 7 cells via hyaluronan. Clin Invest Med, 2011, 34(1): E45-E54.[30] Seiz L, Dorn J, Kotzsch M, Walch A, Grebenchtchikov NI, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J, Diamandis EP, Langer R, Sweep FC, Schmitt M, Magdolen V. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem, 2012, 393(5): 391-401.[31] Hoskins E, Rodriguez-Canales J, Hewitt SM, Elmasri W, Han J, Han S, Davidson B, Kohn EC. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol, 2011, 122(3): 656-662.[32] Clauss A, Ng V, Liu J, Piao HY, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia, 2010, 12(2): 161-172.[33] 李征, 何剪太. 血清血小板衍生生长因子测定在癌症诊断中的应用价值. 中国现代医学杂志, 2011, 21(17): 2072-2076.[34] Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463(7283): 899-905.[35] Li M, Fang X, Wei ZB, York JP, Zhang PM. Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. J Cell Biol, 2009, 185(6): 983-994.[36] Chow JPH, Poon RY, Ma HT. Inhibitory phosphorylation of cyclin-dependent kinase 1 as a compensatory mechanism for mitosis exit. Mol Cell Biol, 2011, 31(7): 1478-1491.[37] Kops GJL, Weaver BAA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer, 2005, 5(10): 773-785.[38] Kang H, Ko J, Jang SW. The role of annexin A1 in expression of matrix metalloproteinase-9 and invasion of breast cancer cells. Biochem Biophys Res Commun, 2012, 423(1): 188-194.[39] Shishido SN, Varahan S, Yuan K, Li XD, Fleming SD. Humoral innate immune response and disease. Clin Immunol, 2012, 144(2): 142-158.[40] Ye XZ, Yu SC, Bian XW. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics, 2010, 37(7): 423-430. |